stockrowRecursion Pharmaceuticals, Inc.
RXRX Healthcare Biotechnology
Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024.
- Revenue
- +258.5%
- EPS
- +39.1%
- Free cash flow
- +33.8%
- Total debt
- −99.2%
Quarter to September 2026, against a year earlier
Follow RXRX
Alert me
Recursion Pharmaceuticals, Inc. (RXRX) EPS (diluted)
Recursion Pharmaceuticals, Inc.'s EPS (diluted) for fiscal 2025 was −$1.44, compared with −$1.69 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$0.90. Over the past ten years it has ranged from −$3.99 (fiscal 2020) to −$0.37 (fiscal 2019); the current reading is higher than 75% of that period. Recursion Pharmaceuticals, Inc. ranks 187th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$1.44 | — |
| FY2024 | −$1.69 | — |
| FY2023 | −$1.58 | — |
| FY2022 | −$1.36 | — |
| FY2021 | −$1.49 | — |
| FY2020 | −$3.99 | — |
| FY2019 | −$2.87 | — |
| FY2019 | −$0.37 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.22 | — |
| Jun 2026 | −$0.25 | — |
| Mar 2026 | −$0.22 | — |
| Dec 2025 | −$0.21 | — |
| 23 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ADMA ADMA Biologics Inc compare | $0.77 |
| VCEL Vericel Corporation compare | $0.65 |
| RXRX Recursion Pharmaceuticals, Inc. | −$0.90 |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$1.69 |
| MBX MBX Biosciences, Inc. compare | −$2.41 |
| PHVS Pharvaris N.V. compare | −$3.05 |
| BHVN Biohaven Ltd. compare | −$3.86 |
| CLDX Celldex Therapeutics, Inc. compare | −$4.35 |
| PVLA Palvella Therapeutics, Inc. compare | −$4.83 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on RXRX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement